Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $2.02 Million - $2.93 Million
-72,926 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $97,762 - $139,064
-3,391 Reduced 4.44%
72,926 $2.15 Million
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $1.63 Million - $2.13 Million
-57,412 Reduced 42.93%
76,317 $2.62 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $3.21 Million - $4.84 Million
133,729
133,729 $4.84 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.77B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Portfolio

Follow Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.